BEI Medical, CryoGen Menorrhagia Ablation Systems Launch April 30
This article was originally published in The Gray Sheet
Executive Summary
Simultaneous FDA approval of BEI Medical Systems' Hydro ThermAblator and CryoGen's HerOption devices for excessive uterine bleeding clears the way for introduction of both systems at the American College of Obstetricians and Gynecologists meeting April 30 in Chicago, the firms say.
You may also be interested in...
AMS’ CryoGen Purchase Anticipates Expanded HerOption Applications
American Medical Systems will seek to extend HerOption endometrial ablation technology for fibroid treatment following the firm's acquisition of CryoGen
AMS’ CryoGen Purchase Anticipates Expanded HerOption Applications
American Medical Systems will seek to extend HerOption endometrial ablation technology for fibroid treatment following the firm's acquisition of CryoGen
Panel Favors First Option, Proposes Study To Address Device Malfunctions
CryoGen should conduct a premarket prospective study of the First Option uterine cryoablation therapy to validate changes made in response to reported device malfunctions, FDA's Obstetrics and Gynecology Devices Panel agreed Jan. 29 in recommending an expanded claim for endometrial ablation.